Teva wins FDA approval for Prolia biosimilar Ponlimsi and secures Xolair biosimilar filing review by the FDA and EMA, strengthening its biosimilars push.

TEL AVIV, Israel and PARSIPPANY, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced three milestones in its biosimilar portfolio, demonstrating continued momentum in the advancement of its Pivot to Growth strategy. The United States (U.S.) Food and Drug Administration (FDA) has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia ® , and Teva's applications for a proposed biosimilar candidate to Xolair ® (omalizumab) have been accepted by both the U.S. FDA and the European Medicines Agency (EMA).

E. Ohman J or Asset Management AB purchased a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 19,680 shares of the company's stock, valued at approximately $614,000. A number of

Hudson Bay Capital Management LP grew its stake in Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) by 87.5% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 225,000 shares of the company's stock after acquiring an additional 105,000 shares during the

TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the “Investors” page on its website.

TEL AVIV, Israel and PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2026 financial results on Wednesday, April 29, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

Stocks are soaring to start the new week, as falling oil prices and bond yields encourage investors

Capital International Investors boosted its stake in Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) by 0.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,727,954 shares of the company's stock after purchasing an additional 18,966 shares during the period.

The Food and Drug Administration approved the drug leucovorin as a treatment for the rare genetic condition cerebral ​folate deficiency on Tuesday—but stopped short of approving it as a treatment for autism in general, an abrupt shift after members of the administration previously mentioned it as a potential therapy for the developmental disorder.

Teva Pharmaceutical Industries Limited (TEVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript